Skip to content

Adjuvance Technologies

Empowering health.

About Us
Our Technology
Our Leadership
- Board of Directors
- Management Team
Investors & Media
Contact

Nature Chemistry: Development of a minimal saponin vaccine adjuvant based on QS-21

By jgardnerJune 1, 2014Publications

Nature Chemistry: Development of a minimal saponin vaccine adjuvant based on QS-21

Adjuvance cofounders report the design, develop and adjuvant activity of novel, truncated QS-21 analogs.

Tejada_nchem.1963

Post navigation

Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer

Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresol

Recent Posts

ADJUVANCE TECHNOLOGIES TO PRESENT AT 2021 BIO DIGITAL
ADJUVANCE TECHNOLOGIES PRESENTS DATA AT THE ANNUAL CONFERENCE ON VACCINOLOGY RESEARCH (ACVR)
ADJUVANCE TECHNOLOGIES ANNOUNCES NIH FUNDING FOR COVID-19 VACCINE RESEARCH
ADJUVANCE TECHNOLOGIES ANNOUNCES $20 MILLION SERIES A INVESTMENT FROM MORNINGSIDE VENTURE INVESTMENTS
Comparative preclinical evaluation of AS01 versus other Adjuvant systems in a candidate herpes zoster glycoprotein E subunit vaccine

Copyright © All rights reserved. Theme Businessbiz by Sensational Theme